FDA approves Oceana's Solesta for treatment of fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration (FDA) has approved Solesta® as a treatment for fecal (bowel) incontinence in adult patients who have failed conservative therapy such as dietary control.

"This is a pivotal development, one that advances Oceana Therapeutics to an exciting new growth stage," said John T. Spitznagel, Oceana's Chairman & CEO. "Moreover, Solesta epitomizes our corporate mission to commercialize specialty therapeutics for unmet medical needs and to achieve optimal outcomes and enhanced patient quality of life."

David S. Tierney, Oceana's President & COO, said, "Solesta was developed in collaboration with Q-Med AB as a minimally invasive injectable gel that can be administered, relatively quickly, in an outpatient setting without the need for anesthesia. This is a significant new treatment option for the many underserved patients who fail conservative therapy and face a life of potential social humiliation and the possibility of severe invasive treatment such as surgery."

"I also want to commend everyone involved in the speedy responses to the items raised about a month ago in the FDA's approvable letter for Solesta," said Tierney. "The turnaround time between the FDA's approvable letter and today's announced marketing approval of Solesta has been, in our view, remarkably fast."

Oceana intends to focus Solesta marketing and medical educational support on colorectal surgeons, specialists in treating bowel incontinence. The Company is also moving expeditiously to put in place marketing materials, build product inventory, and be prepared to ship and launch Solesta during the second half of 2011. "The sooner we get Solesta into the hands of the physicians, the sooner it will be available to patients who can benefit from the product," said Tierney. "So, we intend to push hard for a 3rd quarter U.S. launch, although we realize that is an aggressive target."


Oceana Therapeutics


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Maternal influences on food allergy prevention: A closer look at diet and environment